/XBRANE.ST

XBRANE.ST Stock - Xbrane Biopharma AB (publ)

Q: What is the analyst price target for XBRANE.ST?

Analyst price target information is not currently available for XBRANE.ST.

Q: What is XBRANE.ST's market cap?

Market capitalization information is not currently available for XBRANE.ST.

Healthcare|Biotechnology|STO

$10.88-0.93%

$0.10 (-0.93%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $11.96

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for XBRANE.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.78

52W High$38.25

52W Low$8.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$198.70M	$238.73M	$57.62M	$11.53M	$6.82M
Gross Profit	$180.47M	$35.39M	$41.04M	$-684,000	$2.45M
Gross Margin	90.8%	14.8%	71.2%	-5.9%	35.9%
Operating Income	$-217,922,000	$-310,426,000	$-166,217,000	$-180,397,000	$-224,252,000
Net Income	$-266,220,000	$-388,172,000	$-172,226,000	$-191,012,000	$-226,792,000
Net Margin	-134.0%	-162.6%	-298.9%	-1656.2%	-3324.9%
EPS	$-27.50	$-158.75	$-96.25	$-112.50	$-176.25

Company Overview

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

Visit Website

Earnings History & Surprises

XBRANE.ST

Beat Rate

50%

Last 18 quarters

Avg Surprise

-12.3%

EPS vs Estimate

Beats / Misses

9/9

Last 12 quarters

Latest EPS

$-1.17

Q4 2025

EPS Surprise History

Q1 24

+6.7%

$-0.35vs$-0.38

Q2 24

-233.3%

$-0.30vs$-0.09

Q3 24

-25.0%

$-0.05vs$-0.04

Q4 24

-500.0%

$-0.03vs$-0.01

Q1 25

-400.0%

$-0.03vs$0.01

Q2 25

+133.3%

$0.01vs$-0.03

Q3 25

+1028.5%

$13.82vs$-1.49

Q4 25

-173.3%

$-1.17vs$1.59

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 18, 2026	—	—	—	—
Q4 2025	Oct 24, 2025	$1.59	$-1.17	-173.3%	✗ MISS
Q3 2025	Aug 26, 2025	$-1.49	$13.82	+1028.5%	✓ BEAT
Q2 2025	May 8, 2025	$-0.03	$0.01	+133.3%	✓ BEAT
Q1 2025	Feb 21, 2025	$0.01	$-0.03	-400.0%	✗ MISS
Q4 2024	Oct 24, 2024	$-0.01	$-0.03	-500.0%	✗ MISS
Q3 2024	Aug 28, 2024	$-0.04	$-0.05	-25.0%	✗ MISS
Q2 2024	May 16, 2024	$-0.09	$-0.30	-233.3%	✗ MISS
Q1 2024	Feb 26, 2024	$-0.38	$-0.35	+6.7%	✓ BEAT
Q4 2023	Nov 30, 2023	$-3.06	$-2.78	+9.2%	✓ BEAT
Q3 2023	Aug 29, 2023	$-1.77	$-3.22	-81.9%	✗ MISS
Q2 2023	May 31, 2023	$-1.25	$-2.12	-69.6%	✗ MISS
Q1 2023	Feb 17, 2023	$-1.37	$-2.25	-64.2%	✗ MISS
Q4 2022	Oct 28, 2022	$-1.29	$-1.67	-29.5%	✗ MISS
Q3 2022	Jul 22, 2022	$-3.25	$-1.35	+58.5%	✓ BEAT
Q2 2022	May 5, 2022	$-2.64	$-1.50	+43.2%	✓ BEAT
Q1 2022	Feb 24, 2022	$-2.32	$-1.32	+43.1%	✓ BEAT
Q4 2021	Oct 29, 2021	$-2.32	$-1.83	+21.1%	✓ BEAT
Q3 2021	Aug 13, 2021	$-3.03	$-2.67	+11.9%	✓ BEAT

Frequently Asked Questions about XBRANE.ST

What is XBRANE.ST's current stock price?

Xbrane Biopharma AB (publ) (XBRANE.ST) is currently trading at $10.88 per share. The stock has moved -0.93% today.

What is the analyst price target for XBRANE.ST?

No analyst price targets are currently available for this stock.

What sector is Xbrane Biopharma AB (publ) in?

Xbrane Biopharma AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.

What is XBRANE.ST's market cap?

Xbrane Biopharma AB (publ) has a market capitalization of $0.13 billion, making it a small-cap company.

Does XBRANE.ST pay dividends?

No, Xbrane Biopharma AB (publ) does not currently pay a dividend to shareholders.